Chong Kun Dang Pharmaceutical has filed a patent for donepezil ether palmitate hydrochloride (DEP HCl) and a method for its preparation. DEP HCl offers increased stability by reducing the generation of unknown substances during the preparation process, leading to a sustained-release pharmaceutical composition with improved treatment effects for dementia patients. GlobalData’s report on Chong Kun Dang Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s company profile on Chong Kun Dang Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Chong Kun Dang Pharmaceutical's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

Donepezil ether palmitate hydrochloride for sustained-release pharmaceutical composition

Source: United States Patent and Trademark Office (USPTO). Credit: Chong Kun Dang Pharmaceutical Corporation

The patent application (Publication Number: US20230399298A1) discloses various claims related to an acid addition salt of a compound and a sustained-release pharmaceutical composition. Claim 1 and Claim 2 describe the chemical structures of the acid addition salt and the pharmaceutical composition, respectively. Claim 3 and Claim 4 focus on the sustained-release pharmaceutical composition containing the compound mentioned in Claim 1 and Claim 2. Additionally, Claim 5 and Claim 10 specify that the pharmaceutical composition is intended for preventing or treating dementia, highlighting its potential therapeutic application.

Furthermore, the patent application outlines a method for preparing the acid addition salt mentioned in Claim 1 and Claim 2. Claim 6 details the process involving the reaction of specific compounds with an acid to form the desired salt. Claim 7 provides a step-by-step procedure for preparing the salt, emphasizing the importance of solvent selection and salt formation. Moreover, Claim 8 and Claim 11 list various acids that can be used in the preparation process, while Claim 9 specifies suitable solvents for the reaction. Overall, the patent application presents a comprehensive overview of the acid addition salt, pharmaceutical composition, and the method for their preparation, with a focus on potential applications in dementia prevention and treatment.

To know more about GlobalData’s detailed insights on Chong Kun Dang Pharmaceutical, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies